Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.54 |
| ▸ | MEN1 | O00255 | 7/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20304490 | 0.90 | HDAC1 (0.49) | KMT2AMEN1GAAGPR35HPGD | |
| SCHEMBL20304405 | 0.84 | HDAC3 (0.50) | KMT2AMEN1GAAGPR35AAK1 | |
| SCHEMBL29721874 | 0.80 | KMT2A (0.65) | KMT2AMEN1GAARAB9A | |
| SCHEMBL28734357 | 0.80 | KMT2A (0.65) | KMT2AMEN1GAARAB9A | |
| SCHEMBL14242761 | 0.80 | HDAC1 (0.53) | KMT2AMEN1GAASMN1; SMN2MAPT | |
| SCHEMBL15594368 | 0.79 | KMT2A (0.68) | KMT2AMEN1GAAABL1AAK1 | |
| SCHEMBL15718583 | 0.79 | HPGD (0.64) | KMT2AMEN1GAAABL1AAK1 | |
| SCHEMBL31692494 | 0.79 | HTT (0.64) | KMT2AMEN1GAAABL1HPGD | |
| SCHEMBL25767955 | 0.78 | KDM4E (0.55) | KMT2AMEN1GAAABL1AAK1 | |
| SCHEMBL22394778 | 0.77 | MEN1 (0.51) | KMT2AMEN1GAAHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116096720-B | Dihydropyrrolo [2,3-d ] pyridazin-7-one derivatives, preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-115867547-B | 1H-pyrazole-4-amide derivative, preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2024-12-20 | — | — | CN | disclosed |
| WO-2024067694-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2024-04-04 | — | — | WO | disclosed |
| CN-115485281-B | FGFR and mutation inhibitor thereof, and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| CN-116096720-A | Dihydropyrrolo [2,3-d ] pyridazin-7-one derivatives, preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4169922-A1 | FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-04-26 | — | — | EP | disclosed |
| EP-4169922-A1 | FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-04-26 | — | — | EP | disclosed |
| CN-115485281-A | FGFR and mutation inhibitor thereof, and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2022042613-A1 | 1H-PYRAZOL-4-AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2022-03-03 | — | — | WO | disclosed |
| WO-2022042612-A1 | DIHYDROPYRROLO[2,3-D]PYRIDAZIN-7-ONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2022-03-03 | — | — | WO | disclosed |
| WO-2022042612-A1 | DIHYDROPYRROLO[2,3-D]PYRIDAZIN-7-ONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2022-03-03 | — | — | WO | disclosed |
| WO-2022033532-A1 | FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2022-02-17 | — | — | WO | disclosed |
| WO-2022033532-A1 | FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | FGFR3, FGFR1, FGFR4 | KMT2A 2210/4885MEN1 1023/4885GAA 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.